Article Details

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy ... - 新浪香港

Retrieved on: 2024-04-07 22:11:00

Tags for this article:

Click the tags to see associated articles and topics

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy ... - 新浪香港. View article details on hiswai:

Summary

Bioinformatics underpins the development of autogene cevumeran (BNT122, RO7198457), an mRNA cancer vaccine for pancreatic cancer adjuvant therapy showing promising results in a Phase 1 trial, co-developed by BioNTech and Genentech.

Article found on: portal.sina.com.hk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up